Drug Trial Radar · NCT06660173
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
409
Actual
Start
Nov 7, 2024
Primary completion
Oct 6, 2025
Study completion Nov 10, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
Maridebart CafraglutideDrug
Solution for subcutaneous injection.
PlaceboDrug
Solution for subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)Time frame: Baseline to Week 24
Locations
96 sites in 14 countries. Site status is shown where the registry gives one.
Accel Research Site - Birmingham Clinical Research Unit
Birmingham, Alabama
Anaheim Clinical Trials
Anaheim, California
Hope Clinical Research LLC
Canoga Park, California
Orange County Research Center
Lake Forest, California
San Jose Clinical Trials
San Jose, California
Northeast Research Institute - Neri
Fleming Island, Florida
New Horizon Research Center
Miami, Florida
Florida Institute for Clinical Research
Orlando, Florida
Conquest Research - Winter Park
Winter Park, Florida
Accel Research Site - Neurostudies
Decatur, Georgia
Cedar Crosse Research and Health Care
Chicago, Illinois
Tandem Clinical Research - Marrero
Marrero, Louisiana
DM Clinical - Detroit
Southfield, Michigan
Montana Medical Research
Missoula, Montana
Physicians East
Greenville, North Carolina
Diabetes and Endocrinology Associates of Stark County Inc
Canton, Ohio
Alliance for Multispecialty Research
Norman, Oklahoma
Trial Management Associates - Myrtle Beach
Myrtle Beach, South Carolina
FutureSearch Trials of Neurology
Austin, Texas
Velocity Clinical Research - Dallas
Dallas, Texas
DM Clinical Research - Cyfair Clinical Research Center
Houston, Texas
Southern Endocrinology Associates PA
Mesquite, Texas
Be Well Clinical Studies
Round Rock, Texas
Diabetes and Glandular Disease Clinic
San Antonio, Texas
DM Clinical Research - Martin Diagnostic Clinic
Tomball, Texas
Charlottesville Medical Research Center
Charlottesville, Virginia
Manassas Clinical Research Center Inc
Manassas, Virginia
Eastside Research Associates Health Research
Redmond, Washington
Medizinische Universitaet Graz
Graz, Austria
Krankenhaus der Barmherzigen Brueder Linz
Linz, Austria
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, Austria
Klinik Hietzing
Vienna, Austria
Laiko General Hospital of Athens
Athens, Greece
Athens Medical Center S.A - Iatriko Amarousiou
Marousi, Greece
Athens Medical Center- Iatriko Paleou Falirou
Palaió Fáliro, Greece
Geniko Nosokomeio Peiraia Tzaneio
Piraeus, Greece
General Hospital of Thessaloniki Ahepa
Thessaloniki, Greece
Thermi Clinic S.A.
Thessaloniki, Greece
Queen Mary Hospital, The University of Hong Kong
Hong Kong, Hong Kong
Lausmed Kft
Baja, Hungary
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.